TY - JOUR
T1 - The ARIA approach of Value-Added Medicines
T2 - as-needed treatment in allergic rhinitis
AU - Bousquet, Jean
AU - Toumi, Mondher
AU - Sousa-Pinto, Bernardo
AU - Anto, Josep M
AU - Bedbrook, Anna
AU - Czarlewski, Wienczyslawa
AU - Valiulis, Arunas
AU - Ansotegui, Ignacio J
AU - Bosnic-Anticevich, Sinthia
AU - Brussino, Luisa
AU - Canonica, G Walter
AU - Cecchi, Lorenzo
AU - Cherrez-Ojeda, Ivan
AU - Chivato, Tomas
AU - Costa, Elísio M
AU - Cruz, Alvaro A
AU - Del Giacco, Stefano
AU - Fonseca, Joao A
AU - Gemicioglu, Bilun
AU - Haahtela, Tari
AU - Ivancevich, Juan Carlos
AU - Jutel, Marek
AU - Kaidashev, Igor
AU - Klimek, Ludger
AU - Kvedariene, Violeta
AU - Kuna, Piotr
AU - Larenas-Linnemann, Désirée E
AU - Lipworth, Brian
AU - Morais-Almeida, Mario
AU - Mullol, Joaquim
AU - Papadopoulos, Nikolaos G
AU - Patella, Vincenzo
AU - Pham-Thi, Nhân
AU - Regateiro, Frederico S
AU - Rouadi, Philip W
AU - Samolinski, Boleslaw
AU - Sheikh, Aziz
AU - Taborda-Barata, Luis
AU - Ventura, Maria Teresa
AU - Yorgancioglu, Arzu
AU - Zidarn, Mihaela
AU - Zuberbier, Torsten
N1 - Funding Information:
Conflicts of interest: J. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, and other from KYomed-Innov, outside the submitted work. I.J. Ansotegui reports personal fees from Roxall, UCB, Faes Farma, Sanofi, Bial, Abbott, Bayer, and Organon, outside the submitted work. S. Bosnic-Anticevich reports grants from Teva, personal fees from Teva, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Mylan, outside the submitted work. L. Cecchi reports personal fees from Thermo Fisher, Sanofi, AstraZeneca, and Novartis, outside the submitted work. A.A. Cruz reports personal fees from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Sanofi, Novartis, Eurofarma, and Abdi-Ibrahim, outside the submitted work. S.D. Del Giacco reports grants and personal fees from AstraZeneca, GSK, and Novartis; and personal fees from Sanofi and Chiesi, outside the submitted work. J.A. Fonseca reports and is cofounder of a company that develops mHealth technologies. T. Haahtela reports receiving lecture fees from GSK, Orion Pharma, and Sanofi, outside the submitted work. J.C. Ivancevich reports personal fees from Laboratorios Casasco, Faes Farma, Abbott Ecuador, and Bago Bolivia, outside the submitted work. M. Jutel reports personal fees from ALK-Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Leti, and HAL, during the conduct of the study; and personal fees from GSK, Novartis, Teva, Takeda, and Chiesi, outside the submitted work. V. Kvedariene reports receiving support from Norameda and BerlinCHemie Menarini, which was to help LAAA (Lithuanian Allergy and Asthma Association) organise congresses, outside the submitted work. The author is the President of LAAA, but she did not receive personal fees. P. Kuna reports personal fees from Adamed, Berlin Chemie Menarini, Boehringer Ingelheim, AstraZeneca, Glenmark, Krka, Novartis, Polpharma, GSK, and Sanofi, outside the submitted work. D.E. Larenas-Linnemann reports personal fees from ALK, Allakos, Armstrong, AstraZeneca, Chiesi, DBV Technologies, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Allakos, Gossamer, and Carnot; and grants from Sanofi, AstraZeneca, Lilly, Pfizer, Novartis, Circassia, UCB, GSK, and Purina Institute., outside the submitted work. B. Lipworth reports personal fees from Glenmark, grants and personal fees from Mylan, and grants from Sanofi and AstraZeneca during the conduct of the study; and is the son of a BJL employee of AstraZeneca. J. Mullol reports to be member of Advisory Boards from Sanofi-Genzyme, Regeneron, Novartis, AstraZeneca, and GSK; recieve research grants from Viatris and Noucor/Uriach Group; and personal fees from Mitsubishi-Tanabe, Menarini, UCB, AstraZeneca, GSK, Sanofi, and MSD, outside the submitted work. N.G. Papdopoulos reports receiving grants from Gerolymatos Int., Capricare, and Nutricia and advisories and/or honoraria for talks from ALK, Asit Biotech, AstraZeneca, Biomay, Boehringer Ingelheim, GSK, HAL, Faes Farma, Medscape, Menarini, MSD, Mylan/Meda, Novartis, Nutricia, OM Pharma, Regeneron, Sanofi, and Takeda, outside the submitted work. B. Samoliński reports personal fees from Polpharma, Viatris, Teva, patient ombudsman, Polish Allergology Society; grants and personal fees from AstraZeneca; and grants from GSK, outside the submitted work. T. Zuberbier reports personal fees from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Pfizer, Sanofi, Stallergenes, Takeda, Teva, and UCB; grants and personal fees from Novartis; personal fees from Kryolan and L'Oréal, outside the submitted work; is affiliated with the World Health Organization Initiative “Allergic Rhinitis and Its Impact on Asthma,” is a member of the board of the German Society for Allergy and Clinical Immunology, is board chairman of the European Centre for Allergy Research Foundation, is president of the Global Allergy and Asthma European Network, and is a member of the Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2022 American Academy of Allergy, Asthma & Immunology
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.
AB - Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.
KW - Allergic rhinitis
KW - MASK-air
KW - Repurposing
KW - Treatment
KW - Value-added medicine
U2 - 10.1016/j.jaip.2022.07.020
DO - 10.1016/j.jaip.2022.07.020
M3 - Article
C2 - 35934308
SN - 2213-2198
VL - 10
SP - 2878
EP - 2888
JO - The journal of allergy and clinical immunology. In practice
JF - The journal of allergy and clinical immunology. In practice
IS - 11
ER -